Current Evidence and Future Directions of PCSK9 Inhibition

Recent scientific and therapeutic advances in proprotein convertase subtilisin kexin type 9 (PCSK9) inhibition have opened a chapter in the management of hypercholesterolemia, especially in patients who are inadequately controlled on or intolerant to statins. The two PCSK9 monoclonal antibodies, evo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jiaqian Xu, Michael D Shapiro
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2021
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/1545b531fe6049699ec45ed8e3e0f060
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1545b531fe6049699ec45ed8e3e0f060
record_format	dspace
spelling	oai:doaj.org-article:1545b531fe6049699ec45ed8e3e0f0602021-12-04T16:03:54ZCurrent Evidence and Future Directions of PCSK9 Inhibition10.15420/usc.2020.171758-390X1758-3896https://doaj.org/article/1545b531fe6049699ec45ed8e3e0f0602021-02-01T00:00:00Zhttps://www.uscjournal.com/articleindex/usc.2020.17https://doaj.org/toc/1758-3896https://doaj.org/toc/1758-390XRecent scientific and therapeutic advances in proprotein convertase subtilisin kexin type 9 (PCSK9) inhibition have opened a chapter in the management of hypercholesterolemia, especially in patients who are inadequately controlled on or intolerant to statins. The two PCSK9 monoclonal antibodies, evolocumab and alirocumab, reduce LDL cholesterol by 60% and improve cardiovascular outcomes when taken in addition to statin therapy. More recently, inclisiran, a silencing RNA (siRNA) that inhibits translation of PCSK9 mRNA, demonstrated LDL cholesterol reduction by 45–50% with the advantage of dramatically reduced dose frequency. Other modes of PCSK9 inhibition include small molecule antagonists, vaccines, CRISPR gene editing, and antagonism at various steps of translation, and post-translational processing.Jiaqian XuMichael D ShapiroRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENUS Cardiology Review , Vol 15, Iss , Pp - (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Jiaqian Xu Michael D Shapiro Current Evidence and Future Directions of PCSK9 Inhibition
description	Recent scientific and therapeutic advances in proprotein convertase subtilisin kexin type 9 (PCSK9) inhibition have opened a chapter in the management of hypercholesterolemia, especially in patients who are inadequately controlled on or intolerant to statins. The two PCSK9 monoclonal antibodies, evolocumab and alirocumab, reduce LDL cholesterol by 60% and improve cardiovascular outcomes when taken in addition to statin therapy. More recently, inclisiran, a silencing RNA (siRNA) that inhibits translation of PCSK9 mRNA, demonstrated LDL cholesterol reduction by 45–50% with the advantage of dramatically reduced dose frequency. Other modes of PCSK9 inhibition include small molecule antagonists, vaccines, CRISPR gene editing, and antagonism at various steps of translation, and post-translational processing.
format	article
author	Jiaqian Xu Michael D Shapiro
author_facet	Jiaqian Xu Michael D Shapiro
author_sort	Jiaqian Xu
title	Current Evidence and Future Directions of PCSK9 Inhibition
title_short	Current Evidence and Future Directions of PCSK9 Inhibition
title_full	Current Evidence and Future Directions of PCSK9 Inhibition
title_fullStr	Current Evidence and Future Directions of PCSK9 Inhibition
title_full_unstemmed	Current Evidence and Future Directions of PCSK9 Inhibition
title_sort	current evidence and future directions of pcsk9 inhibition
publisher	Radcliffe Medical Media
publishDate	2021
url	https://doaj.org/article/1545b531fe6049699ec45ed8e3e0f060
work_keys_str_mv	AT jiaqianxu currentevidenceandfuturedirectionsofpcsk9inhibition AT michaeldshapiro currentevidenceandfuturedirectionsofpcsk9inhibition
_version_	1718372720247308288

Current Evidence and Future Directions of PCSK9 Inhibition

Ejemplares similares